Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow

12Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background. In patients with neuroblastoma morphological assessment of BM for residual NB cells is not precise, particularly when the number of tumor cells is small. Procedure. To develop a sensitive and rapid method of detecting NB cells in BM, we assessed the efficiency of flow cytometry (FCM) using markers CD9, CD56, and CD45. The percent of CD9+/ CD56+/CD45- (NB phenotype) cells was determined by FCM in 41 samples (16 patients) at various time points. For confirmation fluorescence in situ hybridization (FISH) for 17q gain was performed. Results. Nineteen of the 22 (86%) samples that were negative by morphology were positive by FCM (>0.006% CD9+/ CD56+/CD45- cells). The longest time to complete the FCM study was 3 hr. In six FISH experiments the sorted CD9+/CD56+/CD45-population had a higher percentage of cells with 17q gain (11.5-95%) compared to a CD56-/ CD45+ internal control population (2-8%). Conclusions. Our preliminary results suggest that FCM determination of the percent of CD9+/ CD56+/CD45- cells is an effective method of rapidly detecting NB cells in BM. © 2005 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Okcu, M. F., Wang, R. Y., Bueso-Ramos, C., Schober, W., Weidner, D., Andrassy, R., … Ater, J. (2005). Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow. Pediatric Blood and Cancer, 45(6), 787–795. https://doi.org/10.1002/pbc.20428

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free